Tango Therapeutics Inc. (TNGX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript
Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript
Tango Therapeutics stock soars on promising pancreatic cancer data
Shares of Tango Therapeutics (TNGX) surged more than 51% on Monday after the clinical-stage biotechnology company reported encouraging early-stage trial results for its experimental cancer treatment, vopimetostat. The drug was tested in combination with Revolution Medicines' daraxonrasib.
Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment
Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.
Avoro Capital Advisors LLC Takes $4.58 Million Position in Tango Therapeutics, Inc. $TNGX
Avoro Capital Advisors LLC acquired a new stake in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 545,000 shares of the company's stock, valued at approximately $4,578,000. Avoro Capital Advisors LLC owned approximately
Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise
Tango Therapeutics, Inc. is downgraded to Hold after a sharp rally, with 2026 positioned as a pivotal, data-driven year. Vopimetostat, the lead PRMT5 inhibitor, advances to a pivotal trial in 2L MTAP-deleted pancreatic cancer, with FDA-aligned design and robust enrollment. TNGX boasts a $343m cash position, partnerships with Gilead and Revolution Medicines, and multiple upcoming data catalysts, but faces fierce competition.
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
Tango Therapeutics stock hits a record high after signing a clinical collaboration with Erasca to test the ERAS-0015/vopimetostat combo in MTAP-deleted RAS-mutant cancers.
Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
